Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Timothy D Clay"'
Publikováno v:
JCO Oncology Practice
The novel 2019 coronavirus disease (COVID-19) pandemic is a global public health emergency. To date, physical distancing and good personal hygiene have been the only effective measures to limit spread. The pandemic has altered routine cancer care, in
Publikováno v:
Journal of Medical Case Reports, Vol 15, Iss 1, Pp 1-9 (2021)
Journal of Medical Case Reports
Journal of Medical Case Reports
Background Immunotherapy has become an efficacious option in the management of solid organ malignancies. Immune-related adverse events including pneumonitis are well described and may be particularly of concern in patients receiving immunotherapy for
Autor:
Timothy D. Clay, Samantha Bowyer
Publikováno v:
Anti-Cancer Drugs. 29:802-805
Febrile illnesses are common in the management of metastatic solid organ malignancies. Traditionally they occur in the setting of immunosuppression and neutropenia owing to cytotoxic therapy necessitating consideration of systemic infections. Systemi
Autor:
Narayan Karanth, Hui K Gan, Louise M. Nott, Carrie Lethborg, Christos S. Karapetis, Sabe Sabesan, Nick Pavlakis, Timothy D. Clay, Hans Prenen, Ellen Heywood, Desmond Yip, Christopher Steer, Eva Segelov, Christopher Jackson, C. Raina MacIntyre, Deme Karikios, Craig Underhill
Publikováno v:
JCO Oncology practice
Cancer has become a prevalent disease, affecting millions of new patients globally each year. The COVID-19 pandemic is having far-reaching impacts around the world, causing substantial disruptions to health and health care systems that are likely to
Autor:
Hongdo Do, Sue-Anne McLachlan, Alexander Dobrovic, Matthew Conron, Vijaya Sundararajan, Melissa M. Moore, Prudence A. Russell, Gavin M. Wright, Timothy D. Clay
Publikováno v:
Pathology. 48:17-24
We sought to investigate the frequency of mutations in epidermal growth factor receptor (EGFR) and Kirsten-RAS (KRAS) by each pathological subtype for patients with resected pulmonary adenocarcinoma as defined by the IASLC/ATS/ERS classification. His
Autor:
Patricia Roxburgh, Martin Forster, Enric Carcereny, Enriqueta Felip, Matthew G Krebs, Bernhard Doger, Leora Horn, Frédéric Triebel, Timothy D. Clay, Julio Antonio Peguero, Margarita Majem, Pawan Bajaj
Publikováno v:
Cancer Research. 80:CT202-CT202
Purpose: Eftilagimod alpha (efti) is a soluble LAG-3 protein that binds to a subset of MHC class II molecules to mediate antigen presenting cell (APC) activation and then CD8 T-cell activation. The stimulation of the dendritic cell network and subseq
Autor:
Patricia Roxburgh, Pawan Bajaj, Matthew G Krebs, Frédéric Triebel, Enric Carcereny, Margarita Majem, Martin Forster, Julio Antonio Peguero, Enriqueta Felip, Bernard Doger, Timothy D. Clay
Publikováno v:
Journal of Clinical Oncology. 38:3100-3100
3100 Background: Eftilagimod alpha (efti) is a soluble LAG-3 protein that binds to a subset of MHC class II molecules to mediate antigen presenting cell (APC) activation and then CD8 T-cell activation. The stimulation of the dendritic cell network an
Autor:
Dennis R. Taaffe, Raphael Chee, Nicolas H. Hart, Robert U. Newton, Daphne Tsoi, Timothy D. Clay, Nigel Spry, Kynan T. Feeney, H. Martin, Andrew Redfern, Christobel Saunders, Daniel A. Galvão
Publikováno v:
Trials
Trials, Vol 19, Iss 1, Pp 1-15 (2018)
Trials, Vol 19, Iss 1, Pp 1-15 (2018)
Background Skeletal metastases present a major challenge for clinicians, representing an advanced and typically incurable stage of cancer. Bone is also the most common location for metastatic breast carcinoma, with skeletal lesions identified in over
Publikováno v:
Pulmonary Circulation
Pulmonary Circulation, Vol 8 (2018)
Pulmonary Circulation, Vol 8 (2018)
Venous thromboembolism (VTE) is a potentially lethal event. Anticoagulation is the cornerstone of treatment. Inferior vena cava filters (IVCFs) may be used in circumstances when anticoagulation is contraindicated or as an adjunct to anticoagulation.
Autor:
Prudence A. Russell, Gavin M. Wright, Benjamin Solomon, Vijaya Sundararajan, Alexander Dobrovic, Matthew Conron, Timothy D. Clay, Hongdo Do, Sue-Anne McLachlan, Melissa M. Moore
Publikováno v:
Medical oncology (Northwood, London, England). 34(10)
Resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) against EGFR mutant lung adenocarcinoma develops after a median of nine to thirteen months. Upregulation of the interleukin-6 (IL-6)/Janus kinase (JAK)/signal tra